Clinical trial
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in…
NCT00244244 · CytRx, Industry · Completed
Key facts
| NCT number | NCT00244244 |
|---|---|
| Title | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS |
| Official title | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS) |
| Lead sponsor | CytRx, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) |
| Intervention type | Drug |
| Interventions | arimoclomol |
| Enrollment | 80 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Oct 26, 2005 |
| Last update posted | Feb 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: